Wellcome Trust - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- GDPH145425D
- Pages: 73
- November 2018
- Total Views:1156
- Region : Europe
- GlobalData
- Equity Research Report
Details
Summary
Wellcome Trust (Wellcome) is a charity that funds research organizations and research communities. It offers funding schemes to support individual researchers, teams and resources. The trust provides funds in areas of biomedical science, public engagement, humanities, innovations, social science, population health, and product development and applied research. It services include funding, grant management, education resources, and investment. The trust offers its education services for PhD students, post-docs and clinicians. It supports scientists, educators, innovators, and artists across the world. The trust works with partner organizations such as academia, business, governments, philanthropy, and civil society. Wellcome is headquartered in London, the UK.
Wellcome Trust-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Wellcome Trust, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Wellcome Trust, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Wellcome Trust, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Wellcome Trust, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Wellcome Trust, Medical Devices Deals, 2012 to YTD 2018 10
Wellcome Trust, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Wellcome Trust, Pharmaceuticals & Healthcare, Deal Details 14
Venture Financing 14
Karuna Pharma Raises USD42 Million in Series A Financing 14
Corinnova Raises USD6.1 Million from Wellcome Trust 16
Azellon Raises USD2 Million in Venture Financing 17
Kymab Raises USD100.5 Million in Series C Financing 19
Aurum Biosciences Raises USD4.5 Million in Venture Financing 21
Nabriva Therapeutics Raises USD120 Million in Series B Financing 22
Kymab Raises USD40 Million in Series B Financing 24
Pcovery Raises USD4 Million in Venture Financing 25
Biocartis Raises USD 40.5 Million In Series E Financing 26
Pcovery Raises USD5.7 Million in Seed Financing 28
Trino Therapeutics Raises USD 12 Million In Series A Financing 29
Canbex Therapeutics Raises USD 3 Million In Venture Financing 31
Partnerships 32
Sigma-Aldrich Enters into Agreement with Sanger Institute 32
AstraZeneca Enters into Research Agreement with Wellcome Trust Sanger Institute 33
Merck Serono Enters into Co-Development Agreement with Institute of Cancer Research and Wellcome Trust 34
Katholieke Universiteit Leuven And Wellcome Trust Enter Into Agreement With Janssen Pharma To Develop Dengue Antiviral Drugs 35
Blueprint Medicines Enters Into Co-Development Agreement With Wellcome Trust Sanger Institute And Massachusetts General Hospital Cancer Center 37
Licensing Agreements 38
Basilea Pharma Enters into Licensing Agreement for Novel PanRAF Kinase Inhibitors 38
Oxford Gene Enters into Licensing Agreement with Wellcome Trust Sanger Institute 39
Equity Offering 40
Microbiotica Spin Off from Wellcome Trust Sanger Institute 40
Debt Offering 41
Karuna Pharma Raises USD3.4 Million in Private Placement of Notes 41
Asset Transactions 42
Orion Biotechnology Switzerland Acquires 5P12-RANTES Molecule from Mintaka and Wellcome Trust 42
Acquisition 43
Ergomed Acquires Haemostatix 43
GlaxoSmithKline Acquires Remaining Stake in GlycoVaxyn for USD190 Million 45
Wellcome Trust-Key Competitors 47
Wellcome Trust-Key Employees 48
Wellcome Trust-Locations And Subsidiaries 49
Head Office 49
Other Locations & Subsidiaries 49
Recent Developments 50
Government and Public Interest 50
Aug 07, 2018: LSHTM to lead vital research into severe corneal infections in low and middle-income countries 50
May 24, 2018: Bristol Professor awarded GBP1.5 million to look deeper into our cell's quality control mechanism 51
May 01, 2018: USD 4.6M boost in search for new malaria drugs 52
Dec 11, 2017: Scientists discover new way to help nerve regeneration in spinal cord injury 54
Dec 08, 2017: GBP3.9m project to support elimination of the world's leading infectious cause of blindness 55
Nov 15, 2017: Improving clinical trials with machine learning 57
Oct 31, 2017: GHIT Fund Accelerates Promising Efforts to Find New Treatments, Vaccines and Diagnostics for Malaria, Tuberculosis, Leishmaniasis and Mycetoma 58
Sep 15, 2017: 'Exciting' discovery on path to develop new type of vaccine to treat global viruses 61
Aug 30, 2017: Tracing single brain cancer cells simplifies complexity of incurable brain cancers, suggesting new treatments, international study finds 63
Aug 07, 2017: CARB-X Funds Scientists Discovering New Antibiotics to Treat Deadly Superbugs 65
Jan 16, 2017: Cancer genetics refine treatment decisions 67
Other Significant Developments 69
Mar 28, 2018: As the GHIT Fund Closes Out First Five Years of R&D for Lifesaving Medical Breakthroughs, It Launches Next Phase, Focusing on Access and Delivery, Bringing Total Investment to 13.2 Billion Yen (USD 123 Million) 69
Dec 07, 2017: New mental health research framework announced 72
Appendix 73
Methodology 73
About GlobalData 73
Contact Us 73
Disclaimer 73
List Of Figure
List of Figures
Wellcome Trust, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Wellcome Trust, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Wellcome Trust, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Wellcome Trust, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Wellcome Trust, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Wellcome Trust, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Wellcome Trust, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Wellcome Trust, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Wellcome Trust, Medical Devices Deals, 2012 to YTD 2018 10
List Of Table
List of Tables
Wellcome Trust, Pharmaceuticals & Healthcare, Key Facts 2
Wellcome Trust, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Wellcome Trust, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Wellcome Trust, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Wellcome Trust, Deals By Therapy Area, 2012 to YTD 2018 9
Wellcome Trust, Medical Devices Deals, 2012 to YTD 2018 10
Wellcome Trust, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Karuna Pharma Raises USD42 Million in Series A Financing 14
Corinnova Raises USD6.1 Million from Wellcome Trust 16
Azellon Raises USD2 Million in Venture Financing 17
Kymab Raises USD100.5 Million in Series C Financing 19
Aurum Biosciences Raises USD4.5 Million in Venture Financing 21
Nabriva Therapeutics Raises USD120 Million in Series B Financing 22
Kymab Raises USD40 Million in Series B Financing 24
Pcovery Raises USD4 Million in Venture Financing 25
Biocartis Raises USD 40.5 Million In Series E Financing 26
Pcovery Raises USD5.7 Million in Seed Financing 28
Trino Therapeutics Raises USD 12 Million In Series A Financing 29
Canbex Therapeutics Raises USD 3 Million In Venture Financing 31
Sigma-Aldrich Enters into Agreement with Sanger Institute 32
AstraZeneca Enters into Research Agreement with Wellcome Trust Sanger Institute 33
Merck Serono Enters into Co-Development Agreement with Institute of Cancer Research and Wellcome Trust 34
Katholieke Universiteit Leuven And Wellcome Trust Enter Into Agreement With Janssen Pharma To Develop Dengue Antiviral Drugs 35
Blueprint Medicines Enters Into Co-Development Agreement With Wellcome Trust Sanger Institute And Massachusetts General Hospital Cancer Center 37
Basilea Pharma Enters into Licensing Agreement for Novel PanRAF Kinase Inhibitors 38
Oxford Gene Enters into Licensing Agreement with Wellcome Trust Sanger Institute 39
Microbiotica Spin Off from Wellcome Trust Sanger Institute 40
Karuna Pharma Raises USD3.4 Million in Private Placement of Notes 41
Orion Biotechnology Switzerland Acquires 5P12-RANTES Molecule from Mintaka and Wellcome Trust 42
Ergomed Acquires Haemostatix 43
GlaxoSmithKline Acquires Remaining Stake in GlycoVaxyn for USD190 Million 45
Wellcome Trust, Key Competitors 47
Wellcome Trust, Key Employees 48
Wellcome Trust, Subsidiaries 49
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Company Profile
Company Profile Title
Summary
Wellcome Trust (Wellcome) is a charity that funds research organizations and research communities. It offers funding schemes to support individual researchers, teams and resources. The trust provides funds in areas of biomedical science, public engagement, humanities, innovations, social science, population health, and product development and applied research. It services include funding, grant management, education resources, and investment. The trust offers its education services for PhD students, post-docs and clinicians. It supports scientists, educators, innovators, and artists across the world. The trust works with partner organizations such as academia, business, governments, philanthropy, and civil society. Wellcome is headquartered in London, the UK.
Wellcome Trust-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Wellcome Trust, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Wellcome Trust, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Wellcome Trust, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Wellcome Trust, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Wellcome Trust, Medical Devices Deals, 2012 to YTD 2018 10
Wellcome Trust, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Wellcome Trust, Pharmaceuticals & Healthcare, Deal Details 14
Venture Financing 14
Karuna Pharma Raises USD42 Million in Series A Financing 14
Corinnova Raises USD6.1 Million from Wellcome Trust 16
Azellon Raises USD2 Million in Venture Financing 17
Kymab Raises USD100.5 Million in Series C Financing 19
Aurum Biosciences Raises USD4.5 Million in Venture Financing 21
Nabriva Therapeutics Raises USD120 Million in Series B Financing 22
Kymab Raises USD40 Million in Series B Financing 24
Pcovery Raises USD4 Million in Venture Financing 25
Biocartis Raises USD 40.5 Million In Series E Financing 26
Pcovery Raises USD5.7 Million in Seed Financing 28
Trino Therapeutics Raises USD 12 Million In Series A Financing 29
Canbex Therapeutics Raises USD 3 Million In Venture Financing 31
Partnerships 32
Sigma-Aldrich Enters into Agreement with Sanger Institute 32
AstraZeneca Enters into Research Agreement with Wellcome Trust Sanger Institute 33
Merck Serono Enters into Co-Development Agreement with Institute of Cancer Research and Wellcome Trust 34
Katholieke Universiteit Leuven And Wellcome Trust Enter Into Agreement With Janssen Pharma To Develop Dengue Antiviral Drugs 35
Blueprint Medicines Enters Into Co-Development Agreement With Wellcome Trust Sanger Institute And Massachusetts General Hospital Cancer Center 37
Licensing Agreements 38
Basilea Pharma Enters into Licensing Agreement for Novel PanRAF Kinase Inhibitors 38
Oxford Gene Enters into Licensing Agreement with Wellcome Trust Sanger Institute 39
Equity Offering 40
Microbiotica Spin Off from Wellcome Trust Sanger Institute 40
Debt Offering 41
Karuna Pharma Raises USD3.4 Million in Private Placement of Notes 41
Asset Transactions 42
Orion Biotechnology Switzerland Acquires 5P12-RANTES Molecule from Mintaka and Wellcome Trust 42
Acquisition 43
Ergomed Acquires Haemostatix 43
GlaxoSmithKline Acquires Remaining Stake in GlycoVaxyn for USD190 Million 45
Wellcome Trust-Key Competitors 47
Wellcome Trust-Key Employees 48
Wellcome Trust-Locations And Subsidiaries 49
Head Office 49
Other Locations & Subsidiaries 49
Recent Developments 50
Government and Public Interest 50
Aug 07, 2018: LSHTM to lead vital research into severe corneal infections in low and middle-income countries 50
May 24, 2018: Bristol Professor awarded GBP1.5 million to look deeper into our cell's quality control mechanism 51
May 01, 2018: USD 4.6M boost in search for new malaria drugs 52
Dec 11, 2017: Scientists discover new way to help nerve regeneration in spinal cord injury 54
Dec 08, 2017: GBP3.9m project to support elimination of the world's leading infectious cause of blindness 55
Nov 15, 2017: Improving clinical trials with machine learning 57
Oct 31, 2017: GHIT Fund Accelerates Promising Efforts to Find New Treatments, Vaccines and Diagnostics for Malaria, Tuberculosis, Leishmaniasis and Mycetoma 58
Sep 15, 2017: 'Exciting' discovery on path to develop new type of vaccine to treat global viruses 61
Aug 30, 2017: Tracing single brain cancer cells simplifies complexity of incurable brain cancers, suggesting new treatments, international study finds 63
Aug 07, 2017: CARB-X Funds Scientists Discovering New Antibiotics to Treat Deadly Superbugs 65
Jan 16, 2017: Cancer genetics refine treatment decisions 67
Other Significant Developments 69
Mar 28, 2018: As the GHIT Fund Closes Out First Five Years of R&D for Lifesaving Medical Breakthroughs, It Launches Next Phase, Focusing on Access and Delivery, Bringing Total Investment to 13.2 Billion Yen (USD 123 Million) 69
Dec 07, 2017: New mental health research framework announced 72
Appendix 73
Methodology 73
About GlobalData 73
Contact Us 73
Disclaimer 73
List Of Figure
List of Figures
Wellcome Trust, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Wellcome Trust, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Wellcome Trust, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Wellcome Trust, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Wellcome Trust, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Wellcome Trust, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Wellcome Trust, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Wellcome Trust, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Wellcome Trust, Medical Devices Deals, 2012 to YTD 2018 10
List Of Table
List of Tables
Wellcome Trust, Pharmaceuticals & Healthcare, Key Facts 2
Wellcome Trust, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Wellcome Trust, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Wellcome Trust, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Wellcome Trust, Deals By Therapy Area, 2012 to YTD 2018 9
Wellcome Trust, Medical Devices Deals, 2012 to YTD 2018 10
Wellcome Trust, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Karuna Pharma Raises USD42 Million in Series A Financing 14
Corinnova Raises USD6.1 Million from Wellcome Trust 16
Azellon Raises USD2 Million in Venture Financing 17
Kymab Raises USD100.5 Million in Series C Financing 19
Aurum Biosciences Raises USD4.5 Million in Venture Financing 21
Nabriva Therapeutics Raises USD120 Million in Series B Financing 22
Kymab Raises USD40 Million in Series B Financing 24
Pcovery Raises USD4 Million in Venture Financing 25
Biocartis Raises USD 40.5 Million In Series E Financing 26
Pcovery Raises USD5.7 Million in Seed Financing 28
Trino Therapeutics Raises USD 12 Million In Series A Financing 29
Canbex Therapeutics Raises USD 3 Million In Venture Financing 31
Sigma-Aldrich Enters into Agreement with Sanger Institute 32
AstraZeneca Enters into Research Agreement with Wellcome Trust Sanger Institute 33
Merck Serono Enters into Co-Development Agreement with Institute of Cancer Research and Wellcome Trust 34
Katholieke Universiteit Leuven And Wellcome Trust Enter Into Agreement With Janssen Pharma To Develop Dengue Antiviral Drugs 35
Blueprint Medicines Enters Into Co-Development Agreement With Wellcome Trust Sanger Institute And Massachusetts General Hospital Cancer Center 37
Basilea Pharma Enters into Licensing Agreement for Novel PanRAF Kinase Inhibitors 38
Oxford Gene Enters into Licensing Agreement with Wellcome Trust Sanger Institute 39
Microbiotica Spin Off from Wellcome Trust Sanger Institute 40
Karuna Pharma Raises USD3.4 Million in Private Placement of Notes 41
Orion Biotechnology Switzerland Acquires 5P12-RANTES Molecule from Mintaka and Wellcome Trust 42
Ergomed Acquires Haemostatix 43
GlaxoSmithKline Acquires Remaining Stake in GlycoVaxyn for USD190 Million 45
Wellcome Trust, Key Competitors 47
Wellcome Trust, Key Employees 48
Wellcome Trust, Subsidiaries 49
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Ask A Question
Our Team Will Assist You in What You Are Looking For
or 
: +91 98100 26150
: ankurgupta1984
Related Reports
Page 130 | 
December 2020
Page 130 | December 2020
Page 131 | November 2020
Page 95 | November 2020
Page 96 | August 2020